Tanios S. Bekaii-Saab, MD, Discusses Sequencing of Agents in HCC Therapy

04/03/2019

At the 2019 Great Debates & Updates in GI Malignancies meeting, Tanios S. Bekaii-Saab, MD, discussed how to best sequence drugs in the treatment of HCC.

Recent News

News

Lutetium Lu 177 Dotatate Gains FDA Approval for Pediatric Patients With SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

04/24/2024

Stephanie Holland

Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients age 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Based on results from the...

04/24/2024

Oncology

News

Gemcitabine Plus Cisplatin and Intensity-Modulated Radiation Therapy Improved Response Rate Among Patients With Unresectable Vulvar Squamous Cell Carcinoma

04/23/2024

Stephanie Holland

Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced,...

Results from the phase 2 NRG...

04/23/2024

Oncology

News

FDA Approves Nogapendekin Alfa Inbakicept for Patients With Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer

04/23/2024

Stephanie Holland

Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.

Based on results from the phase...

04/23/2024

Oncology

News

FDA Approves Adjuvant Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer

04/19/2024

Stephanie Holland

Based on results from the phase 3 ALINA trial, the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer.

Based on results from the phase...

04/19/2024

Oncology

News

IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization

04/19/2024

Amber Denham

According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...

According to phase 2 results,...

04/19/2024

Oncology

News

Elranatamab vs Teclistamab Treatment Among Patients With Triple-Class Exposed/Refractory Multiple Myeloma

04/19/2024

Jordan Kadish

According to findings from an unanchored matching-adjusted indirect comparison, elranatamab exhibited significantly better response and survival outcomes among patients with triple-class exposed/refractory multiple myeloma, compared with...

According to findings from an...

04/19/2024

Oncology

News

Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL

04/18/2024

Amber Denham

According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including BCRi-pretreated patients.

According to phase 3b results...

04/18/2024

Oncology

News

Venetoclax With Low-Dose Cytarabine Demonstrates Efficacy, Tolerability for Patients With AML at First MRD or Oligoblastic Relapse

04/18/2024

Amber Denham

Venetoclax with low-dose cytarabine is well-tolerated and highly effective among patients with acute myeloid leukemia at first measurable residual disease or oligoblastic relapse, according to a phase 2 study.

Venetoclax with low-dose...

04/18/2024

Oncology

News

Adjuvant Alectinib Significantly Improved Disease-Free Survival Among Patients With Resected ALK-Positive Non-Small Cell Lung Cancer

04/18/2024

Stephanie Holland

According to results from the phase 3 ALINA trial, adjuvant alectinib significantly improved disease-free survival among patients with resected ALK-positive stage IB, II, or IIIA non-small cell lung cancer.

According to results from the...

04/18/2024

Oncology

News

Second- or Third-Line Giredestrant Among Patients With ER-Positive, HER2-Negative Advanced Breast Cancer

04/18/2024

Stephanie Holland

According to results from the phase 2 acelERA breast cancer study, giredestrant showed a favorable trend toward benefit in investigator-assessed progression-free survival among previously treated patients with ESR1-mutated, ER-positive,...

According to results from the...

04/18/2024

Oncology